ZuriMED Technologies AG

ZuriMED Technologies AG is a Swiss medical device manufacturer specializing in orthopedic soft tissue repair innovations. The company develops and commercializes the FiberLocker® System, a mechanical rotator cuff augmentation device designed to address the clinical challenge of high postoperative retear rates (24–94%) following rotator cuff repair. The FiberLocker® System provides immediate structural integrity to repaired and injured tendons by mechanically augmenting the repair site, reducing the risk of suture-tendon interface failure ('cheesewiring'). The device has received FDA 510(k) clearance as of February 2025. ZuriMED is based in Zurich and has demonstrated strong institutional partnerships with the University of Zurich, ETH Zurich, and the Balgrist University Hospital, reflecting its commitment to evidence-based product development. The company has secured significant funding, including a Series-A round of 14.5 million CHF (August 2023), and has received recognition through multiple Swiss innovation awards and grants from Innosuisse. ZuriMED actively participates in major orthopedic conferences including Shoulder 360, AANA, and AOSSM, positioning itself as a key player in the orthopedic surgical device market. The organization serves the North American and European markets and continues to expand its international presence.